Bristol Myers Squibb Trial of Carcinoma Treatments Fails to Meet Primary Endpoint
May 16 2022 - 7:54AM
Dow Jones News
By Adriano Marchese
Bristol Myers Squibb Co. said Monday that two treatments for
unresectable or metastatic urothelial carcinoma didn't meet their
primary endpoint in a phase 3 trial.
The company said that the Phase 3 CheckMate-901 trial compared
Opdivo with Yervoy, also known as nivolumab and ipilimumab, to
chemotherapy as a first-line treatment for patients with untreated
unresectable or metastatic urothelial carcinoma.
The New York City-based biopharmaceutical company said that the
trial didn't meet the primary endpoint.
Bristol Myers Squibb said an independent data monitoring
committee recommended that the trial continue to assess other
primary and secondary endpoints.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
May 16, 2022 07:39 ET (11:39 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024
